COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Assessment of PCSO-524 Relative to a Comparator Product

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01564160
Recruitment Status : Completed
First Posted : March 27, 2012
Last Update Posted : December 3, 2012
Pharmalink International Ltd.
Information provided by (Responsible Party):
Nutrasource Diagnostics Inc.

Brief Summary:

A marine lipid oil extract isolated from the New Zealand Greenshell® Mussel, Perna canaliculus (P. canaliculus), contains a unique synergistic blend of marine fatty acids.

The objective of the this study is to evaluate the acute (5-hour) and chronic (21-day) bioavailability of a fixed dose of PCSO-524 compared to a fish oil product in a population of healthy adult participants.

Condition or disease Intervention/treatment Phase
Healthy Dietary Supplement: Fish Oil Dietary Supplement: PCSO-524 Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Official Title: Assessment of the Acute and Chronic Bioavailability of Marine Lipid Fraction PCSO-524 Relative to a Comparator Product.
Study Start Date : April 2012
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Fish oil

Arm Intervention/treatment
Experimental: Arm 1: PCSO-524
Dietary Supplement: PCSO-524
Extract of Greenshell Mussel

Active Comparator: Arm 2: Fish Oil
Fish Oil
Dietary Supplement: Fish Oil
Source of omega-3 fatty acids.

Primary Outcome Measures :
  1. Serum Phospholipid [ Time Frame: Day 0 and Day 21 ]

Secondary Outcome Measures :
  1. Total Serum Lipid [ Time Frame: Day 21 @ 0 hours, 2 hours, 3 hours, 4 hours and 5 hours post-dose ]
  2. Serum Free Fatty Acid [ Time Frame: Day 21 @ 0 hours, 2 hours, 3 hours, 4 hours and 5 hours post-dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • The individual is fluent in English and understands the study requirements
  • The participant is willing and able to comply with all requirements defined within this protocol.
  • The individual is willing to provide written informed consent
  • The individual is male or female
  • The individual is between 18 and 65 years of age
  • The individual's blood EPA+DPA+DHA ≤ 5.2% at screening

Exclusion Criteria:

  • The individual is unable to or refuses to provide written informed consent
  • The individual has taken omega-3 supplements within 3 months of screening.
  • Supplements containing any of the following sources of omega-3s will exclude the individual from the study: fish oil, flax oil, krill oil, green-lipped mussel, chia, perilla, algea
  • The individual's blood EPA+DPA+DHA ≥ 5.2% at screening
  • The individual is female and pregnant or breastfeeding, or plans to be during the trial period
  • The individual has known allergies product ingredients (fish/seafood)
  • The individual has any significant medical illness or condition
  • The individual has reported a history of drug dependence or substance abuse (excluding nicotine)
  • The individual is taking lipid-altering medications (statins, niacin, carnitine, fibrates etc.)
  • The individual is unable to abstain from caffeine, alcohol or physical activity for 24 hours before each treatment visit
  • The individual will be excluded if he or she has any additional conditions that, in the Investigator's opinion, would preclude the participant from completing the study or would not be in the best interest of the subject. This would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01564160

Layout table for location information
Canada, Ontario
Nutrasource Diagnostics Inc
Guelph, Ontario, Canada, N1G0B4
Sponsors and Collaborators
Nutrasource Diagnostics Inc.
Pharmalink International Ltd.
Layout table for investigator information
Principal Investigator: Maggie D Laidlaw, Ph.D Nutrasource Diagnostics
Additional Information:
Layout table for additonal information
Responsible Party: Nutrasource Diagnostics Inc. Identifier: NCT01564160    
Other Study ID Numbers: 11.0202
176412 ( Other Identifier: Health Canada )
12-02-003 ( Other Identifier: Canadian SHIELD Ethics Review Board )
First Posted: March 27, 2012    Key Record Dates
Last Update Posted: December 3, 2012
Last Verified: November 2012
Keywords provided by Nutrasource Diagnostics Inc.:
Fish Oil
Omega-3 Fatty Acids
Green-Lipped Mussel
Omega-score < 5.2%